Clinical remission in patients with severe eosinophilic asthma treated with benralizumab who were randomised to reduce their inhaled corticosteroid/formoterol dose: SHAMAL post-hoc analysis - Vienna 2024

All the way to clinical remission of asthma

Chair(s): Richard Russell, Ramesh J. Kurukulaaratchy

Session type: Poster session

Clinical remission in patients with severe eosinophilic asthma treated with benralizumab who were randomised to reduce their inhaled corticosteroid/formoterol dose: SHAMAL post-hoc analysis

Gilles Devouassoux

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Remission on biologics for severe asthma - 5 years of follow-up

Anne Sofie Bjerrum

Poster

Abstract

Clinical characteristics impacting clinical remission attainment in REALITI-A

Giorgio Walter Canonica

Poster

Abstract

Reducing inhaled corticosteroids in patients well controlled on benralizumab: experience from a tertiary severe asthma service

Rachel Burton

Poster

Abstract

Impact of varying lung function threshold on clinical remission in asthma with FF/UMEC/VI: CAPTAIN post hoc analysis

Ian Douglas Pavord

Poster

Abstract

Characteristics of patients meeting the components of clinical remission: CAPTAIN post hoc analysis

Stephen G Noorduyn

Poster

Abstract

Assessment of the components of clinical remission with moderatesevere asthma after 2452 weeks of treatment: CAPTAIN post hoc analysis

Ian Douglas Pavord

Poster

Abstract

Clinical remission in best performers severe asthmatic patients treated for three years with mepolizumab.

Benedetta Bondi

Poster

Abstract

Clinical remission in patients with severe eosinophilic asthma treated with benralizumab who were randomised to reduce their inhaled corticosteroid/formoterol dose: SHAMAL post-hoc analysis

Gilles Devouassoux

Poster

Abstract

Clinical remission and lung function trajectories among the T2 asthma phenotypes

Vera Veith

Poster

Abstract

Remission of asthma in adolescents and young adults with severe asthma treated with Dupilumab

Marta Jimenez Arroyo

Poster

Abstract

Identifying comorbidities associated with switching patterns of real-world asthma treatment: a drug utilization study

Irene Mommers

Poster

Abstract

Real world clinical outcomes and remission rates among patients with severe asthma on monoclonal antibody therapy over two years

Fred Fyles

Poster

Abstract

Relationship between FeNO suppression and Clinical Remission with Tezepelumab in Severe Asthma

Jessica Gates

Poster

Abstract

Clinical Remission in Severe T2 high Asthma : A real-word analysis with Omalizumab, Mepolizumab and Benralizumab.

Jeanne Vervier

Poster

Abstract

The Impact of Number of Treatable Traits to Clinical Remission in patients with Asthma

Chieko Yoshida

Poster

Abstract

Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab:a post-hoc analysis of the 2-year RELIght study

Andriana Papaioannou

Poster

Abstract

Dupilumab-treated patients with moderate-to-severe asthma are more likely to meet clinical remission criteria: results from the VESTIGE trial

Njira Lugogo

Poster

Abstract

Characteristics of responders and non-responders to Tezepelumab in a complex, real-world severe asthma population

Pujan Patel

Abstract

Clinical remission maintained and improved over time in patients with severe asthma treated with omalizumab

Aykut Cilli

Poster

Abstract

De-escalation of maintenance inhaler therapy in severe asthma in remission on Benralizumab

Valentina Catanzaro

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}